According to Bayer HealthCare’s Diabetes Care Division, DCD, the premier Diabetes Care experts, the UAE market value of diabetes self testing monitoring systems is currently estimated at around Dh 22-25 million, at wholesale prices. This is primarily due to the alarmingly high numbers of diabetes sufferers within the country.
Figures recently published by the Department of Health and Medical Sciences in Dubai, stated the number of patients with diabetes across the entire UAE has reached almost a 20% of the entire population. This is a substantial number, when compared to other parts of the world, where figures generally range between 7%-12%.
Bayer’s DCD is now launching its new Ascensia CONTOUR™ blood glucose meter, a new technology that helps in providing a more accurate and comprehensive diabetes control. "It is Bayer HealthCare’s primary aim to provide the general public with the best that science and technology can offer, and especially to those suffering from diabetes in the UAE,” said Dr. Hazem Al Kurdi, Product Manager, Bayer, DCD.
The new Ascensia CONTOUR™ blood glucose monitoring system is the first and only available system that automatically corrects for common variables that affect accuracy. This unique device was specifically designed by Bayer to make the inaccurate glucose detection of some other monitoring systems a thing of the past.
“The innovative new glucose-testing meter has a number of operational features that make it extremely user-friendly. With no coding required, results can be easily acquired in fifteen seconds. In addition, the Ascensia CONTOUR™ meter needs a small blood sample, which means less pain for the user. Persons with diabetes can rest assured that Bayer has created the Ascensia CONTOUR™ system with their specific needs in mind," added Dr. Hazem Al Kurdi.
The Ascensia CONTOUR™ is expected to be available in UAE pharmacies, no later than early January 2005.
